Michael Trauner

Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

Fibrosis in autoimmune and cholestatic liver disease.

Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice.

Farnesoid X receptor represses hepatic human APOA gene expression.

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

Pathogenesis of primary sclerosing cholangitis.

Bile acid transporters and regulatory nuclear receptors in the liver and beyond.

Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.

Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis.

Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

An In Silico Classification Model for Putative ABCC2 Substrates.

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.

Nuclear receptors as drug targets in cholestatic liver diseases.

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism.

Sulphatation does not appear to be a protective mechanism to prevent oxysterol accumulation in humans and mice.

Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice.

Clinical application of transcriptional activators of bile salt transporters.

Characterization of animal models for primary sclerosing cholangitis (PSC).

Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH).

Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice.

Inflammatory bowel disease alters intestinal bile acid transporter expression.

Pharmacological correction of misfolding of ABC proteins.

Cystic fibrosis related liver disease--another black box in hepatology.

EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.

Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD.

Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.

Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains.

Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.

The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism.

24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.

Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.

Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer.

Reply.

Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.

Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.

Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine.

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.

Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?

A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection.

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.

Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes.

The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial.

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.

A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.

Efficacy and safety of bovine activated factors IIa/VIIa/IXa/Xa in patients with active gastrointestinal bleeding: a proof of concept study.

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.

Prognostic impact of ICG-PDR in patients with hypoxic hepatitis.

Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.

Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.

Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.

Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.

Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.

Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency.

The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss.

Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease.

A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors.

Coagulation parameters and major bleeding in critically ill patients with cirrhosis.

Recent advances in understanding and managing cholestasis.

Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.

The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.

Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters.

DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.

Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.

Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice.

Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit.

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.

Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis.

Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.

Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.

Trends in quality of screening colonoscopy in Austria.

Bile acids in regulation of inflammation and immunity: friend or foe?

Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX).

Metabolic preconditioning protects BSEP/ABCB11 mice against cholestatic liver injury.

Liver Capsule: FXR agonists against liver disease.

Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men.

Vitamin D Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial.

Cancer and liver cirrhosis: implications on prognosis and management.

Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.

Trends in quality of screening colonoscopy in Austria.

Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease.

Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.

The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.

Serum bile acids in patients with hepatopulmonary syndrome.

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

New therapeutic concepts in bile acid transport and signaling for management of cholestasis.

The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.

Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.

Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications.

NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.

Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.

Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications.

Impact of higher-order heme degradation products on hepatic function and hemodynamics.

Circulating bile acids predict outcome in critically ill patients.

Chromosomal instability in HCC: a key function for checkpoint kinase 2.

Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.

Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.

Adiponectin regulates AQP3 via PPARα in human hepatic stellate cells.

Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.

Acid-base disorders in liver disease.

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.

Management of portal hypertension before and after liver transplantation.

Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives.

The impact of thyroid hormones on patients with hepatocellular carcinoma.

Molecular Mechanism of Taurocholate Transport by the Bile Salt Export Pump, an ABC Transporter Associated with Intrahepatic Cholestasis.

Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

FXR controls CHOP expression in steatohepatitis.

Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.

Ursodeoxycholic acid prevents ventricular conduction slowing and arrhythmia by restoring T-type calcium current in fetuses during cholestasis.

Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series.

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Surveillance colonoscopy in Austria: Are we following the guidelines?

The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis.

ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.

AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M.

Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.

PNPLA3 expression and its impact on the liver: current perspectives.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.

The role of TIPS in the management of liver transplant candidates.

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.

Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.

Hepatocyte specific expression of an oncogenic variant of β-catenin results in lethal metabolic dysfunction in mice.

Na -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice.

Colesevelam attenuates cholestatic liver and bile duct injury in mice by modulating composition, signalling and excretion of faecal bile acids.

[C]acetate PET as a tool for diagnosis of liver steatosis.

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.

Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease.

Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.

Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years.

Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice.

Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes.

Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs.

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.

Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy.

miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity.

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.

Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study.

Liver disease in adults with α1-antitrypsin deficiency.

A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome.

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.

Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI.

Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy.

Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis.

Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis.

Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study.

Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver.

High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitis.

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.

Resection rates and safety profile of cold vs. hot snare polypectomy in polyps sized 5-10 mm and 11-20 mm.

Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis.

Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption.

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.

High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.

The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation.

Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.

C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.

Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites.

Liver Injury and Failure in Critical Illness.

Obeticholic acid may increase the risk of gallstone formation in susceptible patients.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.

Guideline-conform statin use reduces overall mortality in patients with compensated liver disease.

The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease.

Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl mouse model.

Detection of Various Microplastics in Human Stool: A Prospective Case Series.

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease.

Impact of adenoma detection rate on detection of advanced adenomas and endoscopic adverse events in a study of over 200,000 screening colonoscopies.

Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.

The challenges of primary biliary cholangitis: What is new and what needs to be done.

Gut-liver axis signaling in portal hypertension.

Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.

The impact of hepatic steatosis on portal hypertension.

The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.

Towards a nationwide implementation of a standardized nutrition and dietetics terminology in clinical practice: a pre-implementation focus group study including a pretest and using the consolidated framework for implementation research.

Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function.

Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects.

The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.

Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease.

Portal hypertensive gastropathy is associated with iron deficiency anemia.

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.

Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes.

E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration.

FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population.

HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson's Disease.

Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH.

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.

Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice.

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.

Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?

Optical control of the nuclear bile acid receptor FXR with a photohormone.

Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.

The role of metabolic lipases in the pathogenesis and management of liver disease.

Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment?

Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

NCOR1 Orchestrates Transcriptional Landscapes and Effector Functions of CD4 T Cells.

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.

Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.

Lysosomal acid lipase is the major acid retinyl ester hydrolase in cultured human hepatic stellate cells but not essential for retinyl ester degradation.

Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series.

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.

Effective medical treatments for PSC needed ASAP - is AESOP the answer?

In Vivo H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T.